🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

✨Thank you to Dr. Inés Luis, Dr. Wolfgang Janni, Dr. Jessica Erdmann-Sager, and Dr. Cristina Kline-Quiroz for sharing their expertise and insights during the session “Follow-Up Care After Treatment for Primary Breast Cancer.” The session addressed advancements and challenges in

🎉 Congratulations to Jennifer Carlisle an outstanding #ASCO25 talk! 🎯 Objective: To optimize the clinical use of amivantamab in NSCLC and provide strategies for managing its dermatologic adverse events. 📊 Key Study Highlights: – EGFR Exon20: CHRYSALIS, PAPILLON – Classical

🚀 Outstanding presentation, Dr. Mariano Provencio, at #ASCO2025! Exciting updated results from CheckMate 77T show perioperative nivolumab continues to improve outcomes in resectable NSCLC! 🎯 Study goals: Compare perioperative NIVO vs PBO in stage IIA-IIIB NSCLC (neoadjuvant

🙏 Thank you to Drs. Nadia Harbeck, Icro Meattini and Elizabeth Rapp Berger for their insightful contributions. “Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?” — A powerful session at #ASCO25 exploring how far we can safely de-escalate treatment in

🚨 From Localized to Metastatic: Navigating the RCC Treatment Landscape Caring for RCC pts means teamwork! 📚 Through real cases, experts explore adjuvant tx, risk, progression & the evolving role of biomarkers in metastatic RCC.👩‍⚕️ Urologist: @JodiMaranchie | UPMC 🧬 Oncologist:

🚀 State-of-the-Art Updates in Colorectal Cancer ASCO 🔬 Biomarker-driven treatments in mCRC 🛡️ Neoadjuvant strategies for localized CRC 📈 Rising young-onset CRC: understanding the drivers 💡 Takeaways: ✅ Every CRC pt needs multidisciplinary discussion! ✅ Identify best-fit

Inspiring talk by Dr. Navneet Singh, MD on "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." Grateful for the insights on expanding screening beyond smokers, leveraging AI, and addressing global disparities. #ASCO25 #LungCancer

🎉 Congratulations to Sonam Puri MD for leading the insightful panel: "Navigating Emerging Therapeutic Decisions in the Treatment of Small Cell Lung Cancer: Cases and Considerations" 🌟 Objective: Explore emerging therapeutic options and decision-making in SCLC care. 📊 Key

🙌🏼Grateful to Dr. Susan Swetter, Dr. Meredith McKean, and Dr. Donald Lawrence for a brilliant session at #ASCO25 "State of the Art: Melanoma 3.0T—Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs" What’s becoming clear is that timing matters. 🔸 Greater efficacy

🚀 Exciting results from Dr. Meghan J. Mooradian at #ASCO2025! The NEO-MEL-T trial shows neoadjuvant dostarlimab + cobolimab (D+C) boosts pathologic responses in high-risk melanoma vs dostarlimab alone! 🎯 Key findings: ✅ MPR rate ↑ with combo: 51.9% (D+C) vs 33.3% (D alone)

🚀 Exciting results from Dr. Ahmad A. Tarhini at #ASCO2025! The EA6194 trial shows neoadjuvant pembro + vidutolimod (P+V) boosts pCR rates in high-risk resectable melanoma! 🎯 Key findings: ✅ Higher pCR with combo: 71% (P+V) vs 48% (P alone) ✅ MPR rate ↑: 79% vs 59% ✅ 1-yr

✨ Relacorilant + Nab‑Paclitaxel: A New Standard in Platinum‑Resistant OC! ✨ 🎯 Objective: Boost survival in platinum‑resistant epithelial ovarian cancer by combining the selective glucocorticoid receptor antagonist relacorilant with weekly nab‑paclitaxel (ROSELLA, phase III).

✨ First FDA-Approved PD‑1 Combo for Anal Cancer! ✨📰 🎯 Objective: Assess efficacy of retifanlimab‑dlwr (Zynyz®) with carboplatin + paclitaxel (1L) and as monotherapy (2L+) in locally recurrent/metastatic SCAC. ✅ Inclusion Criteria: • Adults with inoperable locally

✨🚀 Neoadjuvant Nivolumab + Chemo Boosts Long‑Term Survival in Resectable NSCLC! 🫁💪 🎯 Objective: Evaluate whether adding nivolumab to platinum-based chemotherapy before surgery improves overall survival (OS) in patients with resectable stage IB–IIIA non‑small cell lung

✨🔬 First-Line Triple Combo Doubles Survival in BRAF V600E mCRC! 🌟🩺 🎯 Objective: Verify if adding encorafenib (BRAF inhibitor) and cetuximab (EGFR antibody) to standard mFOLFOX6 chemotherapy improves outcomes in previously untreated BRAF V600E–mutant metastatic colorectal

✨ FDA Greenlights Darolutamide for Metastatic Castration-Sensitive Prostate Cancer✨📰 🎯 Objective: Evaluate darolutamide + ADT (±docetaxel) vs placebo + ADT in the phase III ARANOTE trial (N=669) for mCSPC. ✅ Inclusion Criteria: - Adults with metastatic

🔬 INAVO120: Triple Therapy Breakthrough in PIK3CA+ Advanced Breast Cancer 🧬💊 🎯 Objective: Evaluate OS with inavolisib + palbociclib + fulvestrant vs placebo + palbo/fulv in HR+/HER2– PIK3CA-mutated metastatic BC. ✅ Inclusion: - Endocrine-resistant disease - Relapse during

🧬 KOMET Trial: Selumetinib Shows Promise for Adults with NF1-Related Plexiform Neurofibromas 💊🧠 🎯 Objective: Evaluate efficacy/safety of selumetinib vs placebo in adults with NF1 and inoperable symptomatic plexiform neurofibromas. ✅ Inclusion: Adults with confirmed NF1

🚨 New Hope for EGFR+ NSCLC Patients! 🧬 The FDA grants accelerated approval to datopotamab deruxtecan (Dato-DXd) for patients with locally advanced or metastatic NSCLC harboring EGFR mutations, previously treated with both EGFR TKIs and platinum-based chemotherapy. 👥